Dimopoulos M, Wang M, Maisnar V, et al. Response, progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018, 11(1):49. doi: 10.1186/s13045-018-0583-7.
Advertisement
Articles by Dimopoulos M, Wang M, Maisnar V, et al. Response, progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018, 11(1):49. doi: 10.1186/s13045-018-0583-7.
Advertisement
Latest Updated Articles
- Study Summary: Response and Progression-Free Survival at 18 Months With Lenalidomide and Dexamethasone
Published: October 24th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
2
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
3
Contributor: Why Public Health Keeps Failing—and How to Fix It
4
Pricing and Insurance Networks in Outpatient Surgery Markets
5
